Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Epigenetic profiles of elevated cell free circulating H3.1 nucleosomes

Thursday, September 28, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a publication titled 'Epigenetic profiles of elevated cell free circulating H3.1 nucleosomes as potential biomarkers for non-Hodgkin lymphoma.' This research, conducted by Van den Ackerveken et al., highlights the potential of these nucleosomes as biomarkers, which could significantly improve diagnostic approaches for non-Hodgkin lymphoma. The findings were published in Nature – Scientific Reports 2023.
Price reaction · baseline $13.946 (2023-09-28T18:31:00.000Z) · hit during market hours · 1 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
+0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Potential biomarkers for non-Hodgkin lymphoma identified.
  • Research published in a reputable journal, Nature – Scientific Reports.
  • Findings could enhance cancer diagnostics.

Full Press Release Details

Publication title: ‘Epigenetic profiles of elevated cell free circulating H3.1 nucleosomes as potential biomarkers for non-Hodgkin lymphoma’.
Published in Nature – Scientific Reports 2023
Van den Ackerveken et al

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the publication?

The publication focuses on elevated cell free circulating H3.1 nucleosomes as potential biomarkers for non-Hodgkin lymphoma.

Where was the research published?

The research was published in Nature – Scientific Reports in 2023.

Who conducted the research?

The research was conducted by Van den Ackerveken et al.

What is the significance of these findings?

The findings could enhance diagnostic approaches for non-Hodgkin lymphoma.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare non-Hodgkin lymphoma biomarkers H3.1 nucleosomes Van den Ackerveken Nature Scientific Reports
Last updated: Sep 28, 2023

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk